ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-9098|111|2|243-247

ISSN： 0022-4790

Source： JOURNAL OF SURGICAL ONCOLOGY, Vol.111, Iss.2, 2015-02, pp. : 243-247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Delivery of neoadjuvant chemoradiation for patients with stage II and III rectal cancer is suboptimal

By  

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 66, Iss. 5, 2016-09 ,pp. : 357-358

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic factors for low rectal cancer patients undergoing intersphincteric resection after neoadjuvant chemoradiation

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 8, 2015-06 ,pp. : 1054-1058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence‐free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4231-4241

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 369-375

Karger

Access to resources Recommend Favorite

Low Expression of Transforming Growth Factor Beta-1 in Cancer Tissue Predicts a Poor Prognosis for Patients with Stage III Rectal Cancers

By  

Oncology, Vol. 86, Iss. 3, 2014-03 ,pp. : 159-169

Karger

Access to resources Recommend Favorite